Department of Nephrology, National Center for Global Health and Medicine, 1-21-1 Toyama, Shinjuku-ku, Tokyo, 162-8655, Japan.
Disease Control and Prevention Center, National Center for Global Health and Medicine, Tokyo, Japan.
CEN Case Rep. 2022 Aug;11(3):328-332. doi: 10.1007/s13730-021-00671-1. Epub 2022 Jan 9.
Controlling excessive cytokine secretion is a crucial therapeutic strategy for managing coronavirus disease 2019 (COVID-19). Patients on dialysis are at a high risk of severe disease, given abnormal immune responses that can lead to prolonged inflammation. Moreover, patients undergoing dialysis have limited treatment options, as neither remdesivir nor baricitinib is available. The novel neutralizing monoclonal antibody cocktail REGEN-COV (formerly known as REGN-COV2; casirivimab/imdevimab), recently approved in Japan, is a promising drug for preventing severe diseases. However, there are few reports regarding its use in patients undergoing dialysis in Japan. Herein, we report the safe use of antibody cocktail therapy in patients with COVID-19 on hemodialysis receiving maintenance dialysis in Japan. Infusion reactions were not observed during administration. Due to the increasing number of patients with COVID-19 and the limited capacity of the healthcare system, antibody cocktail therapy needs to be enhanced. Antibody cocktail therapy for severe diseases can be safely administered to patients undergoing dialysis who do not require supplemental oxygen.
控制细胞因子的过度分泌是治疗 2019 年冠状病毒病（COVID-19）的关键治疗策略。由于异常的免疫反应会导致炎症持续，因此透析患者患重病的风险很高。此外，透析患者的治疗选择有限，因为瑞德西韦和巴瑞替尼均不可用。新型中和单克隆抗体鸡尾酒 REGEN-COV（以前称为 REGN-COV2；casirivimab/imdevimab）最近在日本获得批准，是预防严重疾病的有前途的药物。然而，关于其在日本透析患者中的使用的报道很少。在此，我们报告了在日本接受维持性透析的 COVID-19 透析患者中使用抗体鸡尾酒疗法的安全性。给药过程中未观察到输注反应。由于 COVID-19 患者数量不断增加和医疗保健系统的能力有限，需要加强抗体鸡尾酒疗法。对于不需要补充氧气的透析患者，严重疾病的抗体鸡尾酒疗法可以安全使用。
Zotero 插件